Clinical Characteristic and Treatment Options of Patients with G3 Gastroenteropancreatic Neuroendocrine Neoplasms in China Abstract #1444

Introduction: Well differentiated neuroendocrine tumor G3 (NET G3) patients are a special part of neuroendocrine neoplasms with a different biological behavior comparing with other G3 patients.
Aim(s): This study was to investigate the clinical pathological features, the impact of different treatment strategies on their clinical outcomes of NET G3 and neuroendocrine carcinoma (NEC) patients in Chinese populations.
Materials and methods: We retrospectively collected 28 NET G3 patients from oncology departments of three hospitals in China and 38 NEC patients for comparison.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Ru Jia
Keywords: NET G3, NEC, TEMCAP

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1070 Subtype Classification and Clinicopathological Characteristics of 78 Cases with Gastric Neuroendocrine Neoplasms
Introduction: Gastric NENs are a group of neoplasms with diverse clinicopathological features.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang C, Tan H Y, Liu J X, Luo J, ...
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#2143 Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams
Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Ru Jia
Authors: Jia R, Li Y L, Jin Y S, Chen Y, ...
#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine
Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Franziska Briest
#1287 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: Experiences in 116 Chinese Patients
Introduction: Gastric NEN are a heterogeneous group of tumors.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang P, Zhang C, Luo J, Liu J X, ...
Keywords: gastric nen, type 1